3 results on '"Topham, Christina"'
Search Results
2. Dupilumab-Associated Ocular Surface Disease: Clinical Characteristics, Treatment, and Follow-Up.
- Author
-
Bohner A, Topham C, Strunck J, Haynes D, Brazil M, Clements J, Simpson E, and Chamberlain W
- Subjects
- Adolescent, Adult, Aged, Anti-Allergic Agents therapeutic use, Child, Conjunctivitis chemically induced, Conjunctivitis drug therapy, Eye Pain chemically induced, Eye Pain drug therapy, Female, Follow-Up Studies, Glucocorticoids therapeutic use, Humans, Keratitis chemically induced, Keratitis drug therapy, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Tacrolimus therapeutic use, Treatment Outcome, Antibodies, Monoclonal, Humanized adverse effects, Conjunctivitis diagnosis, Dermatitis, Atopic drug therapy, Eye Pain diagnosis, Keratitis diagnosis
- Abstract
Purpose: A consecutive case series of patients with dupilumab-associated ocular surface disease (DAOSD) that describes common ocular symptoms and signs, proposes a symptom disease severity grading system, and describes treatment strategies of DAOSD patients was evaluated., Methods: A retrospective chart review of patients with concomitant dupilumab-treated atopic dermatitis and DAOSD with ophthalmic evaluation between January 2014 and May 2019 was conducted., Results: Twenty-nine patients (mean age 46 years, M/F: 12/17) with 57 ophthalmic exams were identified. The most common ocular symptoms included irritation/pain (n = 28, 97%), redness (n = 24, 83%), pruritus (n = 18, 62%), discharge (n = 18, 62%), and light sensitivity (n = 6, 21%). The most frequent signs included conjunctival injection (n = 18, 62%), superficial punctate keratitis (n = 16, 55%), and papillary reaction (n = 8, 28%). Topical corticosteroids (TCS) (n = 23, 79%), tacrolimus (n = 6, 21%), and artificial tears (n = 7, 24%) were the most commonly used therapies. Of those with follow-up documentation (n = 21), 20 were noted to have partial or complete response with TCS based on symptoms and reduction of signs. Using our proposed symptom-based grading scale, scaled 1 to 5 based on the presence of common symptoms listed above, 66% (n = 19) requiring topical immunomodulating therapy were found in the 'severe' group (≥3 symptoms) and 17% (n = 5) were found in the 'mild' group (≤2 symptoms)., Conclusions: This study provides insight into the commonly presenting ocular signs and symptoms associated with DAOSD and highlights the efficacy of TCS and other immunomodulators in improving symptoms associated with DAOSD. Based on our findings, we propose a symptom-based grading system that can guide nonophthalmic physicians regarding ophthalmology consult., Competing Interests: Eric Simpson is a consultant and investigator for Regeneron and Sanofi. The remaining authors have no conflicts of interest to disclose., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
3. Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.
- Author
-
Haynes D, Strunck JL, Topham CA, Ortega-Loayza AG, Kent G, Cassidy PB, Hu R, Choate K, Wang Z, Liu Y, and Greiling TM
- Subjects
- Adult, Antibodies, Monoclonal, Humanized adverse effects, CARD Signaling Adaptor Proteins genetics, DNA Mutational Analysis, Dermatologic Agents adverse effects, Female, Follow-Up Studies, Gain of Function Mutation, Guanylate Cyclase genetics, Humans, Interleukin-17 analysis, Interleukin-17 antagonists & inhibitors, Interleukin-17 metabolism, Male, Membrane Proteins genetics, Middle Aged, Pityriasis Rubra Pilaris diagnosis, Pityriasis Rubra Pilaris genetics, Pityriasis Rubra Pilaris pathology, Quality of Life, Severity of Illness Index, Skin drug effects, Skin metabolism, Skin pathology, Treatment Outcome, Antibodies, Monoclonal, Humanized administration & dosage, Dermatologic Agents administration & dosage, Pityriasis Rubra Pilaris drug therapy
- Abstract
Importance: Pityriasis rubra pilaris is a rare and disabling cutaneous disease that is frequently recalcitrant to conventional therapies and appears to involve interleukin (IL)-17 overexpression., Objective: To investigate the clinical response and safety of ixekizumab in treating pityriasis rubra pilaris., Design, Setting, and Participants: Single-arm, investigator-initiated trial conducted in adult patients with moderate to severe pityriasis rubra pilaris at a single-center academic university from June 2018 to January 2020. A total of 41 patients were screened, 12 were enrolled, and 11 completed the full duration of therapy. A referred, consecutive sample was used during participant selection. The treatment period and primary outcome occurred over 24 weeks with additional patient follow-up through 36 weeks., Intervention: Subcutaneous administration of ixekizumab, a humanized IgG4 antibody that binds IL-17A, at the US Food and Drug Administration-approved dosing schedule for treatment of psoriasis for 24 weeks., Main Outcomes and Measures: The primary outcome was the mean change in Psoriasis Area and Severity Index at 24 weeks. Secondary outcomes included change in affected body surface area, quality of life, induction of sustained remission, and association of improvement with CARD14 genetic variations and cutaneous cytokine expression., Results: A total of 12 white patients (mean [SD] age, 49.8 [15.1] years; 8 male [67%]) were enrolled between June 2018 and April 2019, with 11 completing the full course of intervention. The mean (SEM) improvements in Psoriasis Area and Severity Index, affected body surface area, and Dermatology Life Quality Index were 15.2 (2.1) (P < .0001), 29.8% (9.3%) (P = .009), and 9.5 (2.5) (P = .004), respectively. The 4 participants with the most improvement in Psoriasis Area and Severity Index at week 24 stayed in remission at week 36 (defined as lack of increase in Psoriasis Area and Severity Index from week 24 through week 36), off therapy. Relative dermal IL-17A expression decreased by a 1.9 log-fold change. No participants had known pathogenic CARD14 variations. There were no serious adverse events., Conclusions and Relevance: In this single-armed trial, ixekizumab was associated with reduced clinical signs and symptoms of pityriasis rubra pilaris in a subset of patients, including those in whom other systemic therapies have failed., Trial Registration: ClinicalTrials.gov Identifier: NCT03485976.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.